{"preliminary_commentary":{"by_channel":{"x_thread":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"CREST","nct_id":"NCT04165317","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=crest-nct04165317. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"CREST","arms":[{"description":"PF-06801591 in combination with Bacillus Calmette Guerin(induction+maintenance).","label":"PF-06801591 + BCG induction and maintenance","type":"EXPERIMENTAL"},{"description":"PF-06801591 in combination with Bacillus Calmette Guerin (induction only).","label":"PF-06801591 + BCG induction only","type":"EXPERIMENTAL"},{"description":"Bacillus Calmette Guerin (induction and maintenance).","label":"BCG induction and maintenance","type":"ACTIVE_COMPARATOR"},{"description":"PF-06801591","label":"BCG Unresponsive CIS","type":"EXPERIMENTAL"},{"description":"PF-06801591","label":"BCG Unresponsive NMIBC","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-12-02","type":"ESTIMATED"},"conditions":["Non-muscle Invasive Bladder Cancer"],"enrollment":{"count":1068,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"PF-06801591","otherNames":["Sasanlimab"],"type":"DRUG"},{"name":"Bacillus Calmette-Guerin","otherNames":["BCG"],"type":"DRUG"}],"last_update":"2026-10-15","lead_sponsor":"Pfizer","official_title":"A Phase 3, Multinational, Randomized, Open-Label, Three Parallel-Arm Study of PF-06801591, an Anti-PD-1 Antibody, in Combination With Bacillus Calmette-Guerin (BCG Induction With or Without BCG Maintenance) Versus BCG (Induction and Maintenance) in Participants With High-Risk, BCG-Naïve Non-Muscle Invasive Bladder Cancer or PF-06801591 as a Single Agent in Participants With BCG-Unresponsive NMIBC","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-12-02","type":"ACTUAL"},"primary_outcomes":[{"measure":"Cohort A: Event Free Survival (EFS) as Assessed by the Investigator: Arm A Versus Arm C","timeFrame":"From randomization (Day 1) to first documentation of high-grade disease, progression of disease, persistence of CIS or death due to any cause, whichever occurred first (maximum follow up duration was up to 257.1 weeks)"}],"references":[{"citation":"Shore ND, Powles TB, Bedke J, Galsky MD, Redorta JP, Ku JH, Kretkowski M, Xylinas E, Alekseev B, Ye D, Guerrero-Ramos F, Briganti A, Kulkarni GS, Brinkmann J, Calella AM, Cesari R, Eccleston A, Michelon E, Vermette J, Wei C, Steinberg GD. Sasanlimab taken together with Bacillus Calmette-Guerin (BCG) compared with BCG alone in people with high-risk non-muscle invasive bladder cancer: a plain language summary. Future Oncol. 2026 Jun;22(13):1487-1499. doi: 10.1080/14796694.2026.2671256. Epub 2026 May 24.","pmid":"42177753","type":"DERIVED"},{"citation":"Shore ND, Powles TB, Bedke J, Galsky MD, Palou Redorta J, Ku JH, Kretkowski M, Xylinas E, Alekseev B, Ye D, Guerrero-Ramos F, Briganti A, Kulkarni GS, Brinkmann J, Calella AM, Cesari R, Eccleston A, Michelon E, Vermette J, Wei C, Steinberg GD. Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. Nat Med. 2025 Aug;31(8):2806-2814. doi: 10.1038/s41591-025-03738-z. Epub 2025 May 31.","pmid":"40450141","type":"DERIVED"},{"citation":"Steinberg GD, Shore ND, Redorta JP, Galsky MD, Bedke J, Ku JH, Kretkowski M, Hu H, Penkov K, Vermette JJ, Tarazi JC, Randall AE, Pierce KJ, Saltzstein D, Powles TB. CREST: phase III study of sasanlimab and Bacillus Calmette-Guerin for patients with Bacillus Calmette-Guerin-naive high-risk non-muscle-invasive bladder cancer. Future Oncol. 2024 May;20(14):891-901. doi: 10.2217/fon-2023-0271. Epub 2024 Jan 8.","pmid":"38189180","type":"DERIVED"}],"start_date":{"date":"2019-12-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer","url":"https://clinicaltrials.gov/study/NCT04165317"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/crest-nct04165317"}